About ustekinumab
Interleukin-12/23 monoclonal antibody
Used for
- Crohn’s disease
- Ulcerative colitis
Usual adult dose
Crohn’s disease or ulcerative colitis: one weight-based IV induction dose, about 6 mg/kg, followed by 90 mg under the skin eight weeks later and every eight weeks.
Common side effects
- Infections
- Headache
- Abdominal pain
- Nausea
Important warnings
- Serious infections can occur; treatment may need to stop during serious infection.
- Screen for tuberculosis before treatment.
- Avoid live vaccines during treatment.
- Rarely, serious allergic reactions or posterior reversible encephalopathy syndrome occur.
Pregnancy
Human pregnancy information is limited; use only when the expected benefit outweighs potential risk.
Breastfeeding
Ustekinumab may enter breast milk; effects on the infant are uncertain.
Interactions
- Avoid live vaccines.
- Other immune-suppressing medicines may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.